| Literature DB >> 18611252 |
Mogens Fenger1, Allan Linneberg, Thomas Werge, Torben Jørgensen.
Abstract
BACKGROUND: Biological systems are interacting, molecular networks in which genetic variation contributes to phenotypic heterogeneity. This heterogeneity is traditionally modelled as a dichotomous trait (e.g. affected vs. non-affected). This is far too simplistic considering the complexity and genetic variations of such networks.Entities:
Mesh:
Year: 2008 PMID: 18611252 PMCID: PMC2483291 DOI: 10.1186/1471-2156-9-43
Source DB: PubMed Journal: BMC Genet ISSN: 1471-2156 Impact factor: 2.797
Summary of the variables in the Inter 99 study used in the SEM-LCA analysis
| Mean (SD) | ||
| Women | Men | |
| Number | 3,345 | 3,169 |
| Age (years) | 45.8 (8.0) | 46.6 (7.8) |
| BMI (kg/height2) | 25.8 (5.1) | 26.8 (4.0) |
| Waist-hip ratio (WH) | 0.80 (0.06) | 0.92 (0.06) |
| Systolic blood pressure | 127 (18) | 134 (17) |
| Diastolic blood pressure | 80 (11) | 85 (11) |
| Total cholesterol (mmol/L) | 5.4 (1.1) | 5.6 (1.1) |
| LDL (mmol/L) | 3.4 (1.0) | 3.7 (1.0) |
| VLDL (mmol/L) | 0.53 (0.28) | 0.67 (0.36) |
| Triglycerides (mmol/L) | 1.15 (1.23) | 1.54 (1.39) |
| C-peptide 0 min (pmol/L) | 577 (256) | 627 (301) |
| C-peptide 30 min (pmol/L) | 1,954 (662) | 2,054 (769) |
| C-peptide 120 min (pmol/L) | 2,394 (967) | 2,245 (1,078) |
| Insulin 0 min (pmol/L) | 41 (28) | 45 (31) |
| Insulin 30 min (pmol/L) | 281 (166) | 302 (201) |
| Insulin 120 min (pmol/L) | 228 (203) | 210 (229) |
| Glucose 0 min (mmol/L) | 5.4 (1.0) | 5.8 (1.2) |
| Glucose 30 min (mmol/L) | 8.2 (1.8) | 9.2 (1.9) |
| Glucose 120 min (mmol/L) | 6.3 (2.0) | 6.2 (2.5) |
| HOMAres | 1.71 (1.61) | 2.00 (1.69) |
| U-albumin/creatine ratio (mg/mmol) | 8.9 (52.4) | 8.4 (60.4) |
All variables except glucose at 120 min and the U-albumin/creatinine ratio are significant different between genders (p < 0.001).
Figure 1The figure illustrates the simplified model used in the present study. As explained in Methods liver symbolize a surrogate of processes in the tissues with focus on the insulin metabolism. C-peptide denotes the secretion of C-peptide and hence insulin from the pancreatic β-cell. The insulin on the right side of the liver indicates the amount of insulin actually reaching the general circulation influencing the metabolism in peripheral tissues. Most of the insulin execute its action in and is internalized by the liver. Glucose and lipids are both metabolised in the liver, but also in many other tissues, in addition to influencing insulin production and secretion in the pancreas. All these processes can of course be modelled, but at the moment it will impose severe computer challenges. Nevertheless, this highly simplistic model turns out to be very efficient in the latent class analysis (see text).
Latent class model for women and men
| Insulin levels at 0, 30 and 120 min after an oral glucose tolerance test (OGTT). | |||||||||
| Glucose and C-peptide levels at 0, 30 and 120 min after OGTT. | |||||||||
| Stage 1 | Stage 2 | ||||||||
| Number of classes | 17 | 18 | 19 | 18 | 18 | 18 | 18 | 18 | 19 |
| Additional covariates | BMI | WH | TG | HDLC | Chol. | BCagec | |||
| df a | 551 | 583 | 615 | 746 | 746 | 746 | 746 | 746 | 1,188 |
| AIC | 85,626 | 81,531 | 8,.472 | 8,.330 | 81,487 | 81,473 | 81,411 | 81,490 | 80,962 |
| BIC | 86,322 | 82,870 | 8,.886 | 82,769 | 82,925 | 82,911 | 82,849 | 82,928 | 82,694 |
| Sample-Size Adjusted BIC | 85,947 | 82,148 | 8,.124 | 81,994 | 82,150 | 82,136 | 82,074 | 82,152 | 81,759 |
| Entropy | 0.876 | 0.868 | 0.859 | 0.872 | 0.862 | 0.873 | 0.872 | 0.871 | 0.879 |
| Chi-tests:b | |||||||||
| AIC | <E-5 | <E-5 | <E-5 | <3*E-4 | <E-5 | <E-5 | <6*E-4 | <E-5 | |
| BIC | <E-5 | - | <E-5 | - | - | <0.24 | - | <0.33 | |
| BICadj | <E-5 | <0.027 | <E-5 | - | <0.75 | <E-5 | - | <E-5 | |
| df | 551 | 583 | 615 | 746 | 746 | 746 | 746 | 746 | 1,188 |
| AIC | 83,973 | 83,840 | 83,792 | 83,643 | 83,792 | 83,726 | 83,688 | 83,722 | 83,226 |
| BIC | 85,237 | 85,181 | 85,210 | 85,084 | 85,233 | 85,166 | 85,129 | 85,162 | 84,962 |
| Sample-Size Adjusted BIC | 84,556 | 84,459 | 84,447 | 84,309 | 84,457 | 84,391 | 84,354 | 84,387 | 84,028 |
| Entropy | 0.886 | 0.883 | 0.882 | 0.888 | 0.881 | 0.881 | 0.884 | 0.884 | 0.898 |
| Chi-tests: | |||||||||
| AIC | <E-5 | <E-5 | <E-5 | <E-5 | <E-5 | <E-5 | <E-5 | <E-5 | |
| BIC | <E-5 | - | <E-5 | - | <0.65 | <E-5 | <0.37 | <0.39 | |
| BICadj | <E-5 | <0.51 | <E-5 | 1.00 | <E-5 | <E-5 | <E-5 | <E-5 | |
adf, degrees of freedom.
bChi-square tests. The models were compared with the immediately preceding model. The models in Stage 2 were compared to the best model in Stage 1 and so on.
cBCage, BMI, cholesterol and age.
The latent class variable was regressed on all covariates (see Figure 1B). All models with higher numbers of classes have lesser goodness-of-fit statistics and are omitted form the table.
Size of classes and distribution of frank diabetes type 2 (DMT2) cases in the classes
| Class | Class size | No DMT2 | % DMT2 | Class size | No DMT2 | % DMT2 |
| 1 | 140 | 2 | 1.43% | 112 | 1 | 0.89% |
| 2 | 93 | 0 | 0.00% | 148 | 2 | 1.35% |
| 3 | 163 | 0 | 0.00% | 133 | 1 | 0.75% |
| 4 | 243 | 0 | 0.00% | 106 | 0 | 0.00% |
| 5 | 233 | 0 | 0.00% | 241 | 4 | 1.66% |
| 6 | 197 | 3 | 1.52% | 222 | 1 | 0.45% |
| 7 | 118 | 0 | 0.00% | 138 | 25 | 18.12% |
| 8 | 129 | 8 | 6.20% | 148 | 0 | 0.00% |
| 9 | 173 | 0 | 0.00% | 160 | 0 | 0.00% |
| 10 | 259 | 0 | 0.00% | 128 | 3 | 2.34% |
| 11 | 176 | 3 | 1.70% | 155 | 2 | 1.29% |
| 12 | 141 | 0 | 0.00% | 88 | 0 | 0.00% |
| 13 | 95 | 0 | 0.00% | 195 | 36 | 18.46% |
| 14 | 90 | 3 | 3.33% | 146 | 16 | 10.96% |
| 15 | 95 | 5 | 5.26% | 135 | 2 | 1.48% |
| 16 | 102 | 1 | 0.98% | 116 | 3 | 2.59% |
| 17 | 103 | 23 | 22.33% | 38 | 0 | 0.00% |
| 18 | 58 | 20 | 34.48% | 179 | 39 | 21.79% |
| 19 | 71 | 11 | 15.49% | 120 | 11 | 9.17% |
| 2,679 | 79 | 2.95% | 2,708 | 146 | 5.39% | |
Dynamic metabolic status and gradients for insulin and C-peptide
| Status | (WHO) | Insulin | C-peptide | ||
| Population | NGTa | 82.5% | Negatived | 30.2% | 65.3% |
| IGTb | 17.5% | Positive | 69.8% | 34.7% | |
| Classes | NGT | 82.7% | Negative | 70.4% | 29.2% |
| IGT | 17.3% | Positive | 29.6% | 70.8% | |
| Population | NGT | 72.8% | Negative | 24.9% | 55.2% |
| IGT | 27.2% | Positive | 75.1% | 44.8% | |
| Classes | NGT | 81.1% | Negative | 81.1% | 41.0% |
| IGT | 18.9% | Positive | 18.9% | 59.0% | |
aNGT, normal glucose tolerance; IGT, impaired glucose tolerance. According to the WHO criteria (ref. 40)
bIGT, defined as glucose at 0 minutes above 6.1 mmol/l and/or glucose at 120 minutes above 7.8 mmol/l
cGradients calculated as the differnece between the 120 min and 30 min levels.
dNegative: negative gradients; Positive: positive gradients
Hardy-Weinberg equilibria
| Number | Genotypes | Frequence | |||||||
| Gene | AAb | Aa | aa | Allele A | Allele a | P-valuea | |||
| HNF4a -3 | Male | 2,908 | 1,996 | 629 | 283 | 0.80 | 0.20 | 8.8E-65 | |
| HNF4a -3 | Female | 3,052 | 2,111 | 667 | 274 | 0.80 | 0.20 | 5.2E-59 | |
| Class | |||||||||
| HNF4a -3 | 1 | 138 | 96 | 25 | 17 | 0.79 | 0.21 | 5.0E-07 | |
| HNF4a -3 | 2 | 221 | 140 | 51 | 30 | 0.75 | 0.25 | 4.3E-08 | |
| HNF4a -3 | 3 | 208 | 142 | 41 | 25 | 0.78 | 0.22 | 1.1E-08 | |
| HNF4a -3 | 10 | 131 | 86 | 27 | 18 | 0.76 | 0.24 | 2.2E-06 | |
| HNF4a -3 | 11 | 85 | 65 | 12 | 8 | 0.84 | 0.16 | 8.7E-05 | |
| HNF4a -3 | 12 | 142 | 98 | 29 | 15 | 0.79 | 0.21 | 2.5E-05 | |
| HNF4a -3 | 15 | 125 | 95 | 13 | 17 | 0.81 | 0.19 | 3.6E-11 | |
| HNF4a -3 | 17 | 185 | 126 | 41 | 18 | 0.79 | 0.21 | 2.8E-05 | |
| HNF4a -3 | 3 | 182 | 134 | 30 | 18 | 0.82 | 0.18 | 6.2E-08 | |
| HNF4a -3 | 7 | 90 | 73 | 10 | 7 | 0.87 | 0.13 | 4.5E-05 | |
aOnly genes with p-value below the Bonferoni corrected p-value are shown
bThe most abundant allele is arbitrary labelled A
Heritability of the traits shown in Table T1
| Heritability | ||||||||
| Class | Trait | Gene | Numbera | Additive | Total | F-test | p-value | |
| Gender | Noneb | |||||||
| 5 | HOMAbeta | IL6-2 | 223 | 0.01 | 0.10 | 48.83 | <1E-16 | |
| 9 | Triglycerides | AP2β | 163 | 0.15 | 0.54 | 20.25 | <1E-16 | |
| 17 | U-albumin | AGRP | 100 | 0.31 | 0.33 | 15.06 | 2E-6 | |
| 17 | U-alb/crea | AGRP | 100 | 0.32 | 0.34 | 15.17 | 2E-6 | |
| 19 | Ins30 | PPAR | 71 | 0.08 | 0.47 | 17.45 | 1E-6 | |
| 5 | U-alb/crea | HNF4a-1 | 236 | 0.02 | 0.08 | 13.52 | 3E-6 | |
| 8 | Triglycerides | AGT-1 | 141 | 0.11 | 0.25 | 17.28 | <1E-16 | |
| 13 | Triglycerides | ARβ3 | 190 | 0.01 | 0.10 | 23.35 | <1E-16 | |
| 15 | U-alb/crea | HNF4a-1 | 129 | 0.04 | 0.13 | 14.37 | 2E-6 | |
| 15 | U-albumin | HNF4a-1 | 129 | 0.05 | 0.13 | 14.15 | 3E-6 | |
| 16 | U-albumin | HNF4a-1 | 113 | 0.16 | 0.35 | 17.96 | <1E-16 | |
| 16 | Triglycerides | HNF4a-2 | 112 | 0.13 | 0.29 | 14.76 | 2E-6 | |
| 17 | U-albumin | PGC1 | 37 | 0.21 | 0.96 | 19.72 | 2E-6 | |
| 19 | U-albumin | AGT-1 | 119 | 0.12 | 0.25 | 29.41 | <1E-16 | |
| 19 | U-alb/crea | AGT-2 | 119 | 0.11 | 0.24 | 28.81 | <1E-16 | |
aNumber of individuals included in the test
bNumber of heritabilities detected for any trait
Summary of average of two-gene genetic variance (mean) as the fraction of total phenotypic variance stratified into subpopulations by LCA.
| The significance level for inclusion of cases corrected for multiple comparisons is 6.1E-06 | ||||||
| Minimum | Average | Maximum | Fraction | |||
| Total variance | 29 | 97 | 270 | |||
| LCA/non-LCAa | ||||||
| Additive variance | 9 | 29 | 78 | 29.6% | ||
| LCA/non-LCA | ||||||
| Dominant variance | 6 | 19 | 50 | 19.3% | ||
| LCA/non-LCA | ||||||
| Epistasis | 14 | 50 | 153 | 51.1% | ||
| LCA/non-LCA | ||||||
| | 2,188 | |||||
| | 26.5% | |||||
| | 156 | |||||
| Total variance | 39 | 97 | 430 | |||
| LCA/non-LCA | ||||||
| Additive variance | 9 | 29 | 118 | 30.0% | ||
| LCA/non-LCA | ||||||
| Dominant variance | 7 | 17 | 57 | 18.5% | ||
| LCA/non-LCA | ||||||
| Epistasis | 19 | 50 | 257 | 51.5% | ||
| LCA/non-LCA | ||||||
| | 2,042 | |||||
| | 24,7% | |||||
| | 146 | |||||
aIncrease in average genetic variance in the classes relative to the genetic variance before stratification in to classes by LCA.
Detected interactions in genders before and after SEM -LCA.
| Significance level | ||||
| 0.0017 | 2.5 E-9 | |||
| 1 Detected in both gender and LCA | 245 | 56.3% | 196 | 45.1% |
| 2 Not detected in either gender or LCA | 61 | 14.0% | 68 | 15.6% |
| 3 Detected in both LCA but not in any gender | 97 | 22.3% | 133 | 30.6% |
| 4 Detected only in gender | 2 | 0.5% | 2 | 0.5% |
| 5 Detected in one LCA and in gender | 23 | 5.3% | 23 | 5.3% |
| 6 Detected in one LCA but not in gender | 7 | 1.6% | 13 | 3.0% |
| Full agreement between both gender and LCA (1+2) | 306 | 70.3% | 264 | 60.7% |
| Detected in one or both LCA but not in gender (3+6) | 104 | 23.9% | 146 | 33.6% |
| Actual number of possible interactions | 378 | |||
| SNPs with no interactions (equivalent for both scenarios): TCF1 | HNF4α-6 | |||
Number of interactions between the 30 SNPs included in this study at two Bonferoni corrected significance levels corresponding to a 30 SNP study (0.0017) and to a future 20-million-SNP scenario (2.5 E-9). Percentage indicates the fraction of possible number of interactions for 30 SNPs (i.e., 435)
Genes and classes with no interactions (20 million SNP significance level)
| Women | Men | |
| Genes with no interactions in any classes and any traits: | TCF1, HNF4α-6 | TCF1, HNF4α-6, MCHR1 |
| Classes with no interactions at 0 minutes: | ||
| Insulin | 13, 14, 16, 17, | 4, 12, 16, |
| C-peptide | 13, 16, | 4, |
| Glucose | 18 | 17 |
| Classes with no interactions at 30 minutes: | ||
| Insulin | 7, | 17 |
| C-peptide | 18 | 17 |
| Glucose | 18 | 17 |
| Classes with no interactions at 120 minutes: | ||
| Insulin | 7, 13, 16, | 12, |
| C-peptide | 18 | 17 |
| Glucose | 7, | |